Erratum: Genetic variations in the SOCS3 gene in patients with Graves' ophthalmopathy (J Clin Pathol (2015) 68 (448-452) DOI: 10.1136/jclinpath-2014-202751);Genetic variations in the SOCS3 gene in patients with Graves' ophthalmopathy

Journal of Clinical Pathology

Volumn 68, Issue 6, 2015, Pages 448-452

  Yan, Ruijia ^a   Yang, Junjie ^a   Jiang, Ping ^a   Jin, Ling ^a   Ma, Jing ^a   Huang, Rong ^a   Ma, Nan ^a   Jiang, Fagang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; MESSENGER RNA; RADIOACTIVE IODINE; SUPPRESSOR OF CYTOKINE SIGNALING 3; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID SURGERY; WESTERN BLOTTING; GENE FREQUENCY; GENETICS; METABOLISM; RISK FACTOR;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84929653005     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202751corr1     Document Type: Erratum

References (35)

1. Lindholm J, Laurberg P. Hyperthyroidism, exophthalmos, and goiter: historical notes on the orbitopathy. Thyroid 2010;20:291-300.
2. Khoo TK, Bahn RS. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid 2007;17:1013-18.
3. Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. Thyroid 2008;18:953-8.
4. Kuriyan AE, Phipps RP, Feldon SE. The eye and thyroid disease. Curr Opin Ophthalmol 2008;19:499-506.
5. Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ 2009;338:b560.
6. Bednarczuk T, Hiromatsu Y, Fukutani T, et al. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur J Endocrinol 2003;148:13-18.
7. Bednarczuk T, Kurylowicz A, Hiromatsu Y, et al. Association of G-174C polymorphism of the interleukin-6 gene promoter with Graves' ophthalmopathy. Autoimmunity 2004;37:223-6.
8. Petrone A, Giorgi G, Galgani A, et al. CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Thyroid 2005;15:232-8.
9. Han SZ, Zhang SH, Li R, et al. The common-318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients. Int J Immunogenet 2006;33:281-7.
10. Syed AA, Simmonds MJ, Brand OJ, et al. Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2007;67:663-7.
11. Esteghamati A, Khalilzadeh O, Mobarra Z, et al. Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients. Eur J Intern Med 2009;20:424-8.
12. Khalilzadeh O, Mojazi AH, Tahvildari M, et al. Pretibial myxedema is associated with polymorphism in exon 1 of CTLA-4 gene in patients with Graves' ophthalmopathy. Arch Dermatol Res 2009;301:719-23.
13. Liu YH, Chen RH, Chen WC, et al. Disease association of the CD103 polymorphisms in Taiwan Chinese Graves' ophthalmopathy patients. Ophthalmology 2010;117:1645-51.
14. Liao WL, Chen RH, Lin HJ, et al. The association between polymorphisms of B7 molecules (CD80 and CD86) and Graves' ophthalmopathy in a Taiwanese population. Ophthalmology 2011;118:553-7.
15. Yoshimura A. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J Med 2009;58:73-83.
16. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007;7:454-65.
17. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003;4:1169-76.
18. Kile BT, Alexander WS. The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 2001;58:1627-35.
19. Yoshimura A, Suzuki M, Sakaguchi R, et al. SOCS, inflammation, and autoimmunity. Front Immunol 2012;3:20.
20. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008;28:477-87.
21. Persico M, Capasso M, Russo R, et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 2007;57:507-15.
22. Ekelund E, Saaf A, Tengvall-Linder M, et al. Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis. Am J Hum Genet 2006;78:1060-5.
23. Talbert ME, Langefeld CD, Ziegler J, et al. Polymorphisms near SOCS3 are associated with obesity and glucose homeostasis traits in Hispanic Americans from the Insulin Resistance Atherosclerosis Family Study. Hum Genet 2009;125:153-62.
24. Li P, Tiwari HK, Lin W, et al. Genetic association analysis of 30 genes related to obesity in a European American population. Int J Obes (Lond) 2013;38:724-9.
25. Ezra DG, Krell J, Rose GE, et al. Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy. Journal of Clinical Pathology 2012;65:608-13.
26. Tosato G, Cohen JI. Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr Protoc Immunol 2007;7:7-22.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods 2001;25:402-8.
28. Xiao Z, Xiao J, Jiang Y, et al. A novel method based on ligase detection reaction for low abundant YIDD mutants detection in hepatitis B virus. Hepatol Res 2006;34:150-5.
29. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001;19:378-87.
30. Dey BR, Furlanetto RW, Nissley P. Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun 2000;278:38-43.
31. Baxter RC, Twigg SM. Actions of IGF binding proteins and related proteins in adipose tissue. Trends Endocrinol Metab 2009;20:499-505.
32. Zhao P, Deng Y, Gu P, et al. Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy. Exp Eye Res 2013;107:65-73.
33. Zheng YY, Wang LF, Fan XH, et al. Association of suppressor of cytokine signalling 3 polymorphisms with insulin resistance in patients with chronic hepatitis C. J Viral Hepat 2013;20:273-80.
34. Sun LP, Ma XL, Liu HX, et al. No association of polymorphisms in the suppressor of cytokine signaling (SOCS)-3 with rheumatoid arthritis in the Chinese Han population. Genet Mol Res 2010;9:1518-24.
35. Jamshidi Y, Snieder H, Wang X, et al. Common polymorphisms in SOCS3 are not associated with body weight, insulin sensitivity or lipid profile in normal female twins. Diabetologia 2006;49:306-10.